Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05923684 · ClinicalTrials.gov registry record · NA

NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making

A NA study of Prostate Cancer, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05923684 is a NA study of Prostate Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05923684, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigators will report the top five sentences from each consultation across key content areas (cancer prognosis, life expectancy, erectile dysfunction, urinary incontinence, and irritative urinary symptoms) to both patients and physicians within 2 weeks of the consultation.

Conditions Studied

Interventions

  • BEHAVIORAL NLP-based Feedback

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-11-15
Est. Completion 2026-07-15
Phase NA

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT05923684

The ClinicalTrials.gov registry entry for NCT05923684 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which NLP-based Feedback is the first listed.

NCT05923684 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05923684 about?

NCT05923684 is a clinical study titled "NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making". In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. The investigators will recruit from the practices of up to 10 physicians who typically see these patients. The investigators will report the ...

What is the current status of trial NCT05923684?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-11-15. Estimated completion is 2026-07-15.

What conditions does trial NCT05923684 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05923684?

The interventions under investigation include: NLP-based Feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT05923684?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05923684 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.